Insmed Incorporated or Mesoblast Limited: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Insmed Incorporated and Mesoblast Limited, two prominent players, offer a fascinating study in contrasts. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, peaking in 2023. This reflects their aggressive expansion strategy. In contrast, Mesoblast maintained a more conservative approach, with expenses fluctuating modestly, peaking in 2015 and then stabilizing. By 2023, Mesoblast's SG&A costs were approximately 85% lower than Insmed's, highlighting their disciplined cost management. However, missing data for 2024 suggests caution in drawing definitive conclusions. This analysis underscores the strategic choices companies make in balancing growth and cost control, offering valuable insights for investors and industry watchers alike.